BRIM Biotechnology, Inc.

BRIM Biotechnology, Inc. is a Taiwan-based company focused on researching and developing drugs and therapies to combat and cure diseases. Its lead product candidate, BRM421, is a neurotrophic peptide that has completed a Phase 3 clinical trial for dry eye disease. The company is also developing BRM424 for neurotrophic keratitis (Phase 1 completed), BRM411 for glaucoma (Phase 2 completed), BRM412 for wet age-related macular degeneration (Phase 2 completed), and BRM521 for osteoarthritis (pre-clinical). Founded in 2013, BRIM Biotechnology is headquartered in Taipei, Taiwan.